In last trading session, Bicycle Therapeutics Plc ADR (NASDAQ:BCYC) saw 0.63 million shares changing hands with its beta currently measuring 1.34. Company’s recent per share price level of $9.69 trading at $0.06 or 0.62% at ring of the bell on the day assigns it a market valuation of $669.19M. That closing price of BCYC’s stock is at a discount of -195.87% from its 52-week high price of $28.67 and is indicating a premium of 1.14% from its 52-week low price of $9.58. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.32 million shares which gives us an average trading volume of 392.24K if we extend that period to 3-months.

For Bicycle Therapeutics Plc ADR (BCYC), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.47. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.81 in the current quarter.

Bicycle Therapeutics Plc ADR (NASDAQ:BCYC) trade information

Upright in the green during last session for gaining 0.62%, in the last five days BCYC remained trading in the red while hitting it’s week-highest on Wednesday, 03/12/25 when the stock touched $9.69 price level, adding 10.61% to its value on the day. Bicycle Therapeutics Plc ADR’s shares saw a change of -30.79% in year-to-date performance and have moved -5.28% in past 5-day. Bicycle Therapeutics Plc ADR (NASDAQ:BCYC) showed a performance of -21.35% in past 30-days. Number of shares sold short was 4.22 million shares which calculate 14.79 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 38 to the stock, which implies a rise of 74.5% to its current value. Analysts have been projecting 26 as a low price target for the stock while placing it at a high target of 55. It follows that stock’s current price would drop -168.32% in reaching the projected high whereas dropping to the targeted low would mean a loss of -168.32% for stock’s current value.

Bicycle Therapeutics Plc ADR (BCYC) estimates and forecasts

This year revenue growth is estimated to fall -2.02% from the last financial year’s standing.

10 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 8.67M for the same. And 10 analysts are in estimates of company making revenue of 7.86M in the next quarter. Company posted 19.53M and 9.36M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -0.87% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -19.49% while estimates for its earnings growth in next 5 years are of -9.01%.

Bicycle Therapeutics Plc ADR (NASDAQ:BCYC)’s Major holders

Insiders are in possession of 1.75% of company’s total shares while institution are holding 92.06 percent of that, with stock having share float percentage of 93.70%. Investors also watch the number of corporate investors in a company very closely, which is 92.06% institutions for Bicycle Therapeutics Plc ADR that are currently holding shares of the company. BAKER BROS. ADVISORS LP is the top institutional holder at BCYC for having 9.4 million shares of worth $190.26 million. And as of 2024-06-30, it was holding 18.0796 of the company’s outstanding shares.

The second largest institutional holder is DEEP TRACK CAPITAL, LP, which was holding about 3.49 million shares on 2024-06-30. The number of shares represents firm’s hold over 6.7135 of outstanding shares, having a total worth of $70.65 million.

On the other hand, Price (T.Rowe) Health Sciences Fund and Harbor Small Cap Growth Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 1.2 shares of worth $11.62 million or 2.51% of the total outstanding shares. The later fund manager was in possession of 868.5 shares on Oct 31, 2024 , making its stake of worth around $8.42 million in the company or a holder of 1.82% of company’s stock.